Christina Franssen

Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

THERAtRAME SA is a drug discovery start-up company based in Liege, Belgium. The Belgian company aims to become a leader in the development and positioning of novel cancer therapies by exploring new target areas to develop innovative cancer therapies. THERAtRAME's discovery platform integrates unique sets of technologies to discover, develop, and position new drugs to beat reluctant cancers. The company exploits the latest scientific discoveries highlighting the unexpected importance of trna epitranscriptomics dynamics in cancer. THERAtRAME is looking for a drug discovery assay developer leader to join their team. The company was founded by Francesca Rapino, Pierre Close, and has a team of experienced professionals with backgrounds in life sciences, medico-marketing, and biotech venture creations.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

THERAtRAME SA is a drug discovery start-up company based in Liege, Belgium. The Belgian company aims to become a leader in the development and positioning of novel cancer therapies by exploring new target areas to develop innovative cancer therapies. THERAtRAME's discovery platform integrates unique sets of technologies to discover, develop, and position new drugs to beat reluctant cancers. The company exploits the latest scientific discoveries highlighting the unexpected importance of trna epitranscriptomics dynamics in cancer. THERAtRAME is looking for a drug discovery assay developer leader to join their team. The company was founded by Francesca Rapino, Pierre Close, and has a team of experienced professionals with backgrounds in life sciences, medico-marketing, and biotech venture creations.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere.

Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

THERAtRAME SA is a drug discovery start-up company based in Liege, Belgium. The Belgian company aims to become a leader in the development and positioning of novel cancer therapies by exploring new target areas to develop innovative cancer therapies. THERAtRAME's discovery platform integrates unique sets of technologies to discover, develop, and position new drugs to beat reluctant cancers. The company exploits the latest scientific discoveries highlighting the unexpected importance of trna epitranscriptomics dynamics in cancer. THERAtRAME is looking for a drug discovery assay developer leader to join their team. The company was founded by Francesca Rapino, Pierre Close, and has a team of experienced professionals with backgrounds in life sciences, medico-marketing, and biotech venture creations.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Exothera SA is a Belgian company that manufactures and develops viral vector and nucleic acid. The private company is based in Jumet, Belgium. The company was founded in 2020 by José Fernandez Castillo, Hugues Bultot. The CEO is Thibault Jonckheere.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium.

Société Régionale d'Investissement de Wallonie SA (SRIW) is a private equity & venture capital firm , a subsidiary of Region of Wallonia founded in 1979. Société Régionale d'Investissement de Wallonie SA is headquartered in Liege, Belgium.